Oshry, L. J., Lederman, R. I., Gagnon, H., Fikre, T., Gundersen, D. A., Revette, A. C., Odai-Afotey, A., Kantor, O., Hershman, D. L., Crew, K. D., Keating, N. L., Freedman, R. A., & Ko, N. Y. (2025). Racial discrimination among women seeking breast cancer care. Npj Breast Cancer, 11(1). https://doi.org/10.1038/s41523-025-00717-y

Johansson, H., Guerrieri-Gonzaga, A., Gandini, S., Bertelsen, B.-E., Macis, D., Serrano, D., Mellgren, G., Lazzeroni, M., Thomas, P. S., Crew, K. D., Kumar, N. B., Briata, I. M., Galimberti, V., Viale, G., Vornik, L. A., Aristarco, V., Buttiron Webber, T., Spinaci, S., Brown, P. H., … DeCensi, A. (2024). Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. Npj Breast Cancer, 10(1). https://doi.org/10.1038/s41523-024-00616-8

Fraenkel, M., Novack, V., Mizrakli, Y., Koretz, M., Siris, E., Norton, L., Shafat, T., & Geffen, D. B. (2022). Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00388-z

Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Diéras, V., Carey, L. A., Gianni, L., Piccart, M. J., Loibl, S., Goldenberg, D. M., Hong, Q., Olivo, M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00467-1

Jakuboski, S. H., McDonald, J. A., & Terry, M. B. (2022). Do current family history-based genetic testing guidelines contribute to breast cancer health inequities? Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00391-4

Wojnarowicz, P. M., Escolano, M. G., Huang, Y.-H., Desai, B., Chin, Y., Shah, R., Xu, S., Yadav, S., Yaklichkin, S., Ouerfelli, O., Soni, R. K., Philip, J., Montrose, D. C., Healey, J. H., Rajasekhar, V. K., Garland, W. A., Ratiu, J., Zhuang, Y., Norton, L., … Benezra, R. (2021). Anti-tumor effects of an ID antagonist with no observed acquired resistance. Npj Breast Cancer, 7(1). https://doi.org/10.1038/s41523-021-00266-0

Goodwin, P. J., Dowling, R. J. O., Ennis, M., Chen, B. E., Parulekar, W. R., Shepherd, L. E., Burnell, M. J., Vander Meer, R., Molckovsky, A., Gurjal, A., Gelmon, K. A., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Whelan, T. J., Hobday, T. J., Rastogi, P., Rabaglio-Poretti, M., Lemieux, J., … Stambolic, V. (2021). Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 7(1). https://doi.org/10.1038/s41523-021-00275-z